Lataa...

Emodin Reverses Gemcitabine Resistance of Pancreatic Cancer Cell Lines Through Inhibition of IKKβ/NF-κB Signaling Pathway

BACKGROUND: Pancreatic cancer is one of the most malignant tumors, and gemcitabine has been considered as the standard treatment and been widely utilized as a first-line drug for advanced pancreatic cancer, but gemcitabine-resistance always occurs after a short period of treatment. METHODS: Two panc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Onco Targets Ther
Päätekijät: Tong, Hongfei, Huang, Zhen, Chen, Hui, Zhou, Bin, Liao, Yi, Wang, Zhaohong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2020
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7537840/
https://ncbi.nlm.nih.gov/pubmed/33061461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S253691
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!